{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:40:30Z","timestamp":1784929230647,"version":"3.55.0"},"reference-count":120,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC111-2314-B-038-017"],"award-info":[{"award-number":["NSTC111-2314-B-038-017"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2314-B-038-098"],"award-info":[{"award-number":["111-2314-B-038-098"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2314-B-038-142"],"award-info":[{"award-number":["111-2314-B-038-142"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST111-2314-B-038-122"],"award-info":[{"award-number":["MOST111-2314-B-038-122"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology","award":["NSTC111-2314-B-038-017"],"award-info":[{"award-number":["NSTC111-2314-B-038-017"]}]},{"name":"Ministry of Science and Technology","award":["111-2314-B-038-098"],"award-info":[{"award-number":["111-2314-B-038-098"]}]},{"name":"Ministry of Science and Technology","award":["111-2314-B-038-142"],"award-info":[{"award-number":["111-2314-B-038-142"]}]},{"name":"Ministry of Science and Technology","award":["MOST111-2314-B-038-122"],"award-info":[{"award-number":["MOST111-2314-B-038-122"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Colorectal cancer (CRC) is one of the most prevalent malignant tumors, and it contributes to high numbers of deaths globally. Although advances in understanding CRC molecular mechanisms have shed significant light on its pathogenicity, current treatment options, including combined chemotherapy and molecular-targeted agents, are still limited due to resistance, with almost 25% of patients developing distant metastasis. Therefore, identifying novel biomarkers for early diagnosis is crucial, as they will also influence strategies for new targeted therapies. The proto-oncogene, c-Met, a tyrosine kinase that promotes cell proliferation, motility, and invasion; c-MYC, a transcription factor associated with the modulation of the cell cycle, proliferation, apoptosis; and cyclin D1 (CCND1), an essential regulatory protein in the cell cycle, all play crucial roles in cancer progression. In the present study, we explored computational simulations through bioinformatics analysis and identified the overexpression of c-Met\/GSK3\u03b2\/MYC\/CCND1 oncogenic signatures that were associated with cancer progression, drug resistance, metastasis, and poor clinical outcomes in CRC. We further demonstrated the anticancer activities of our newly synthesized quinoline-derived compound, NSC772864, against panels of the National Cancer Institute\u2019s human CRC cell lines. The compound exhibited cytotoxic activities against various CRC cell lines. Using target prediction tools, we found that c-Met\/GSK3\u03b2\/MYC\/CCND1 were target genes for the NSC772864 compound. Subsequently, we performed in silico molecular docking to investigate protein\u2013ligand interactions and discovered that NSC772864 exhibited higher binding affinities with these oncogenes compared to FDA-approved drugs. These findings strongly suggest that NSC772864 is a novel and potential antiCRC agent.<\/jats:p>","DOI":"10.3390\/cells12020340","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T02:10:32Z","timestamp":1673921432000},"page":"340","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-9768","authenticated-orcid":false,"given":"Ntlotlang","family":"Mokgautsi","sequence":"first","affiliation":[{"name":"Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan"},{"name":"Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"School of Post-baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-0053","authenticated-orcid":false,"given":"Yan-Jiun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0178-6530","authenticated-orcid":false,"given":"Alexander T. H.","family":"Wu","sequence":"additional","affiliation":[{"name":"The Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"Clinical Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"T.M.U. Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-5182","authenticated-orcid":false,"given":"Hsu-Shan","family":"Huang","sequence":"additional","affiliation":[{"name":"Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan"},{"name":"Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan"},{"name":"Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/0008-5472.CAN-14-2240","article-title":"Colorectal cancer heterogeneity and targeted therapy: A case for molecular disease subtypes","volume":"75","author":"Linnekamp","year":"2015","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor K.R.A.S. and B.R.A.F. mutation status","volume":"29","author":"Folprecht","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Hitre","year":"2009","journal-title":"N. Engl.J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s10620-014-3444-4","article-title":"The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening","volume":"60","author":"Grady","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/CEJ.0000000000000019","article-title":"Mismatch repair pathway: Molecules, functions, and role in colorectal carcinogenesis","volume":"23","author":"Sameer","year":"2014","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","article-title":"HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers","volume":"56","author":"Moosavi","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: A MET-driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature04872","article-title":"New signals from the invasive front","volume":"441","author":"Christofori","year":"2006","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc779","article-title":"Scatter-factor and semaphorin receptors: Cell signalling for invasive growth","volume":"2","author":"Trusolino","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tcb.2015.07.012","article-title":"Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression","volume":"25","author":"Ye","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1158\/1535-7163.MCT-10-0124","article-title":"Pharmacologic inactivation of kinase suppressor of Ras1 sensitizes epidermal growth factor receptor and oncogenic Ras-dependent tumors to ionizing radiation treatment","volume":"9","author":"Xiao","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.canlet.2006.07.007","article-title":"Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome","volume":"248","author":"Kammula","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clcc.2018.02.013","article-title":"c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival","volume":"17","author":"Lee","year":"2018","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10336","DOI":"10.1002\/jcp.27701","article-title":"c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells","volume":"234","author":"Lin","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_22","first-page":"147","article-title":"Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer","volume":"1","author":"Olivero","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1158\/1078-0432.CCR-13-0423","article-title":"Increased TGF-\u03b1 as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells","volume":"19","author":"Troiani","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/cas.13092","article-title":"Functional and therapeutic relevance of hepatocyte growth factor\/c-MET signaling in synovial sarcoma","volume":"107","author":"Imura","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.08.002","article-title":"Tracking, MET de-addiction in lung cancer: A road towards the oncogenic target","volume":"60","author":"Pilotto","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.celrep.2013.11.001","article-title":"Combined Wnt\/\u03b2-catenin, Met, and CXCL12\/CXCR4 signals characterize basal breast cancer and predict disease outcome","volume":"5","author":"Holland","year":"2013","journal-title":"Cell Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/0008-5472.CAN-07-5172","article-title":"Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer","volume":"68","author":"Tuynman","year":"2008","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/neuonc\/nos299","article-title":"Wnt\/\u03b2-catenin signaling is a key downstream mediator of M.E.T. signaling in glioblastoma stem cells","volume":"15","author":"Kim","year":"2013","journal-title":"Neuro Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1242\/jcs.00384","article-title":"GSK-3: Tricks of the trade for a multi-tasking kinase","volume":"116","author":"Doble","year":"2003","journal-title":"J. Cell Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a008052","article-title":"Wnt signaling in cancer","volume":"4","author":"Polakis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/OTT.S95101","article-title":"Advances in targeted and immunobased therapies for colorectal cancer in the genomic era","volume":"9","author":"Seow","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dvdy.24527","article-title":"Wnt is necessary for mesenchymal to epithelial transition in colorectal cancer cells","volume":"247","author":"Schwab","year":"2018","journal-title":"Dev. Dyn."},{"key":"ref_33","first-page":"5126","article-title":"Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer","volume":"62","author":"Boon","year":"2002","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"(2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330\u2013337.","DOI":"10.1038\/nature11252"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.281.5382.1509","article-title":"Identification of c-MYC as a target of the APC pathway","volume":"281","author":"He","year":"1998","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Beaulieu, M.E., Castillo, F., and Soucek, L. (2020). Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells, 9.","DOI":"10.3390\/cells9041038"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11684-018-0650-z","article-title":"The MYC transcription factor network: Balancing metabolism, proliferation and oncogenesis","volume":"12","author":"Carroll","year":"2018","journal-title":"Front. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2009.05.012","article-title":"Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study","volume":"114","author":"Darcy","year":"2009","journal-title":"Gynecol Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.humpath.2013.01.012","article-title":"8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy","volume":"44","author":"Fromont","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_40","first-page":"1808","article-title":"Gain of chromosome 8q23-24 is a predictive marker for lymph node positivity in colorectal cancer","volume":"9","author":"Ghadimi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-3835(94)90198-8","article-title":"Investigation of c-myc oncogene amplification in colorectal cancer","volume":"81","author":"Kozma","year":"1994","journal-title":"Cancer Lett."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lee, K.S., Kwak, Y., Nam, K.H., Kim, D.W., Kang, S.B., Choe, G., Kim, W.H., and Lee, H.S. (2015). c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0139727"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1007\/s13277-015-3726-2","article-title":"Clinical and prognostic value of M.E.T. gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients","volume":"36","author":"Seo","year":"2015","journal-title":"Tumour. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"54627","DOI":"10.18632\/oncotarget.10559","article-title":"MET amplification in metastatic colorectal cancer: An acquired response to E.G.F.R. inhibition, not a de novo phenomenon","volume":"7","author":"Raghav","year":"2016","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0463.2004.apm1120109.x","article-title":"Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas","volume":"112","author":"Bondi","year":"2004","journal-title":"Apmis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E7697","DOI":"10.1073\/pnas.1710366114","article-title":"Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC","volume":"114","author":"Satoh","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0968-0004(00)89005-2","article-title":"D-type cyclins","volume":"20","author":"Sherr","year":"1995","journal-title":"Trends Biochem. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/15384101.2019.1706903","article-title":"The double dealing of cyclin D1","volume":"19","author":"Tchakarska","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: Small R.N.A.s with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12935-019-0802-5","article-title":"Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis","volume":"19","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","article-title":"MicroRNA-21 regulates expression of the P.T.E.N. tumor suppressor gene in human hepatocellular cancer","volume":"133","author":"Meng","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wang, H. (2020). MicroRNAs and Apoptosis in Colorectal Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155353"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2174\/092986711795328382","article-title":"Quinoline as a privileged scaffold in cancer drug discovery","volume":"18","author":"Solomon","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0968-0896(00)00179-6","article-title":"Synthesis of substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: Evaluation of structure-activity relationships for cytotoxicity","volume":"8","author":"Chen","year":"2000","journal-title":"Bioorganic Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/hmg\/ddq008","article-title":"Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent D.N.A. breaks","volume":"19","author":"Kerzendorfer","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1083\/jcb.134.3.757","article-title":"Induction of neuronal apoptosis by camptothecin, an inhibitor of D.N.A. topoisomerase-I: Evidence for cell cycle-independent toxicity","volume":"134","author":"Morris","year":"1996","journal-title":"J. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","article-title":"Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy","volume":"12","author":"Somasundaram","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1517\/14656566.8.14.2359","article-title":"Sunitinib","volume":"8","author":"Rini","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mokgautsi, N., Kuo, Y.C., Tang, S.L., Liu, F.C., Chen, S.J., Wu, A.T.H., and Huang, H.S. (2022). Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (G.B.M.) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures. Cancers, 14.","DOI":"10.3390\/cancers14010262"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ali, A.A., Lee, Y.R., Chen, T.C., Chen, C.L., Lee, C.C., Shiau, C.Y., Chiang, C.H., and Huang, H.S. (2016). Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154278"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmech.2015.05.015","article-title":"Discovery of 5-(2\u2032,4\u2019-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-\u03baB ligand (R.A.N.K.L.)-induced osteoclastogenesis","volume":"98","author":"Lee","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejmech.2011.10.059","article-title":"Synthesis, anti-proliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives","volume":"47","author":"Lee","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1016\/j.bmc.2009.09.033","article-title":"Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues","volume":"17","author":"Huang","year":"2009","journal-title":"Bioorganic Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1016\/j.bmc.2008.05.072","article-title":"Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives","volume":"16","author":"Huang","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Matthews, H., Hanison, J., and Nirmalan, N. (2016). \u201cOmics\u201d-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives. Proteomes, 4.","DOI":"10.3390\/proteomes4030028"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bartha, \u00c1., and Gy\u0151rffy, B. (2021). TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052622"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/bioinformatics\/bty623","article-title":"GECO: Gene expression correlation analysis after genetic algorithm-driven deconvolution","volume":"35","author":"Najafov","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1186\/gb-2007-8-9-r183","article-title":"The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists","volume":"8","author":"Huang","year":"2007","journal-title":"Genome Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ijc.33283","article-title":"muTarget: A platform linking gene expression changes and mutation status in solid tumors","volume":"148","author":"Nagy","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","article-title":"GSCALite: A web server for gene set cancer analysis","volume":"34","author":"Liu","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/81.14.1088","article-title":"Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm","volume":"81","author":"Paull","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"W609","DOI":"10.1093\/nar\/gkq300","article-title":"PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach","volume":"38","author":"Liu","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drudis.2010.11.002","article-title":"The graphical representation of ADME-related molecule properties for medicinal chemists","volume":"16","author":"Ritchie","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mokgautsi, N., Wen, Y.T., Lawal, B., Khedkar, H., Sumitra, M.R., Wu, A.T.H., and Huang, H.S. (2021). An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3\u03b2\/\u03b2-Catenin\/STAT3\/CD44 Suppressor with Anti-Glioblastoma Properties. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052464"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1021\/jm0492002","article-title":"A bioavailability score","volume":"48","author":"Martin","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: An advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminform."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4155\/fmc.14.114","article-title":"Pharmacophore modeling for COX-1 and -2 inhibitors with LigandScout in comparison to Discovery Studio","volume":"6","author":"Temml","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Mokgautsi, N., Wang, Y.C., Lawal, B., Khedkar, H., Sumitra, M.R., Wu, A.T.H., and Huang, H.S. (2021). Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1\/CDK4\/PLK1\/CD44 in Cancer Types. Cancers, 13.","DOI":"10.3390\/cancers13112523"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"W234","DOI":"10.1093\/nar\/gkz240","article-title":"NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis","volume":"47","author":"Zhou","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/pmic.201400515","article-title":"FunRich: An open access standalone functional enrichment and interaction network analysis tool","volume":"15","author":"Pathan","year":"2015","journal-title":"Proteomics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acs.jcim.5b00713","article-title":"Assessing the Growth of Bioactive Compounds and Scaffolds over Time: Implications for Lead Discovery and Scaffold Hopping","volume":"56","author":"Jasial","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.0.CO;2-F","article-title":"\u201cScaffold-Hopping\u201d by Topological Pharmacophore Search: A Contribution to Virtual Screening","volume":"38","author":"Schneider","year":"1999","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Shave, S., Blackburn, E.A., Adie, J., Houston, D.R., Auer, M., Webster, S.P., Taylor, P., and Walkinshaw, M.D. (2015). UFSRAT: Ultra-fast Shape Recognition with Atom Types\u2014The discovery of novel bioactive small molecular scaffolds for FKBP12 and 11\u03b2HSD1. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116570"},{"key":"ref_94","first-page":"2033","article-title":"Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells","volume":"9","author":"Huyen","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014An emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopha.2014.10.007","article-title":"Quinoline: A promising antitubercular target","volume":"68","author":"Keri","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17460441.2017.1319357","article-title":"An overview of quinoline as a privileged scaffold in cancer drug discovery","volume":"12","author":"Musiol","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.003","article-title":"Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184\/GPCPD1\/ lysophosphatidic acid axis","volume":"523","author":"Huang","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e001038","DOI":"10.1136\/jitc-2020-001038","article-title":"Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response","volume":"8","author":"Qi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/0929867324666171006165942","article-title":"Sunitinib in the Treatment of Thyroid Cancer","volume":"26","author":"Ferrari","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?","volume":"80","author":"Ravaud","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/hep.26258","article-title":"MAT2B-GIT1 interplay activates MEK1\/ERK 1 and 2 to induce growth in human liver and colon cancer","volume":"57","author":"Peng","year":"2013","journal-title":"Hepatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-019-1116-x","article-title":"m(6)A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000011849","article-title":"Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma","volume":"55","author":"Maeda","year":"1998","journal-title":"Oncology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1038\/s41467-019-12108-6","article-title":"The CXCL5\/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis","volume":"10","author":"Curtis","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41419-020-02870-7","article-title":"FBX8 promotes metastatic dormancy of colorectal cancer in liver","volume":"11","author":"Zhu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/pr.117.013755","article-title":"Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs","volume":"69","author":"Coussens","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/ejcts\/ezv323","article-title":"Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases","volume":"49","author":"Schweiger","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/modpathol.2012.150","article-title":"Combined analysis of K.R.A.S. and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer","volume":"26","author":"Voutsina","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: Principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_113","first-page":"4807","article-title":"MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality","volume":"29","author":"Matos","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1038\/s41467-021-26967-5","article-title":"ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation","volume":"12","author":"Gu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1158\/1078-0432.CCR-03-0751","article-title":"Cyclin D1, p53, and p21Waf1\/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer","volume":"10","author":"Bali","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0215(20010920)95:5<302::AID-IJC1052>3.0.CO;2-#","article-title":"Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21(WAF1\/CIP1) expression and correlates with patient survival","volume":"95","author":"Holland","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.7314\/APJCP.2014.15.7.3133","article-title":"Histopathological features of colorectal cancer in Al-Madinah region of Saudi Arabia: 8 years experience","volume":"15","author":"Albasri","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41389-019-0123-5","article-title":"Cell division cycle associated 5 promotes colorectal cancer progression by activating the ERK signaling pathway","volume":"8","author":"Shen","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10434-001-0729-6","article-title":"Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer","volume":"8","author":"Macmillan","year":"2001","journal-title":"Ann. Surg Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/2\/340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:07:40Z","timestamp":1760119660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/2\/340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":120,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12020340"],"URL":"https:\/\/doi.org\/10.3390\/cells12020340","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]}}}